Scilex Holding Co
SCLXNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $30.3M | $56.6M | $46.7M | $38.0M | $31.3M | $23.6M |
| Operating income | −$346.0M | −$83.4M | −$105.4M | −$50.6M | −$1.0M | −$6,276 |
| Net income | −$374.1M | −$72.8M | −$114.3M | −$23.4M | $783,438 | −$6,276 |
| Total assets | $365.0M | $93.0M | $101.3M | $86.5M | $139.9M | $199,484 |
| Total liabilities | $576.7M | $285.6M | $274.2M | $50.3M | $9.2M | $180,760 |
| Equity | −$207.8M | −$192.6M | −$172.9M | $36.2M | −$8.7M | $18,724 |
| EPS (diluted) | $-36.48 | $-8.05 | $-1.28 | $-0.17 | $0.05 | $0.00 |
| Shares out. | 243.3M | 166.2M | 145.8M | 17.3M | 17.3M | 3.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1143.7%
- Net margin
- −1236.4%
- Return on equity
- 180.0%
- Return on assets
- −102.5%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 158.0%
- Debt / equity
- —
- Book value / share
- $-0.85
- Revenue growth (YoY)
- −46.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -22.99distress
- Accruals / assets
- −103.5%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Strong return on equity (>15%)
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 15, 2026
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2026
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2024
- NT 10-Qmissed a reporting deadline ↗Aug 16, 2021
- NT 10-Qmissed a reporting deadline ↗May 17, 2021
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 157,966 | 1.3 | -6.6% |
| Apr 30, 2026 | 169,136 | 2.3 | +6.4% |
| Apr 15, 2026 | 158,978 | 3.5 | -15.4% |
| Mar 31, 2026 | 187,953 | 6.5 | -1.5% |
| Mar 13, 2026 | 190,787 | 5.3 | -13.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventMay 11, 2026
- Entered a material agreement · Regulation FD disclosureMay 5, 2026
- Entered a material agreementApr 28, 2026
- Regulation FD disclosureMar 13, 2026
- Regulation FD disclosureMar 13, 2026
- Entered a material agreement · Unregistered equity saleFeb 20, 2026
- Modified shareholder rights · Amended charter or bylawsFeb 3, 2026
- Entered a material agreementFeb 2, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.